DK2214693T3 - Anvendelse af melanocortiner til behandling af insulinfølsomhed - Google Patents
Anvendelse af melanocortiner til behandling af insulinfølsomhed Download PDFInfo
- Publication number
- DK2214693T3 DK2214693T3 DK08846334.4T DK08846334T DK2214693T3 DK 2214693 T3 DK2214693 T3 DK 2214693T3 DK 08846334 T DK08846334 T DK 08846334T DK 2214693 T3 DK2214693 T3 DK 2214693T3
- Authority
- DK
- Denmark
- Prior art keywords
- arg
- xaa
- cys
- ala
- misc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (12)
1. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ved behandling af insulinresistens i et individ ved perifer indgivelse, hvor melanocortinreceptor-4-agonisten er: Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50; eller et farmaceutisk acceptabelt salt deraf.
2. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 1, hvor individet er fed eller overvægtig.
3. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 1, hvor individet har en normal vægt eller er slank.
4. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 2 eller 3, hvor det fede, overvægtige, normalvægtige eller slanke individ lider af type II diabetes.
5. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge et af kravene 1-4, hvor den perifere indgivelse er oral, subkutan, intraperitoneal, intramuskulær, intravenøs, rektal, transdermal eller intra-nasal.
6. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 5, hvor indgivelsen er kontinuerlig, en gang i timen, fire gange dagligt, tre gange dagligt, to gange dagligt, en gang dagligt, en gang hver anden dag, to gange om ugen, en gang om ugen, en gang hver anden uge, en gang om måneden eller en gang hver anden måned.
7. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 6, hvor indgivelsen er kontinuerlig.
8. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 6, hvor indgivelsen er en gang dagligt.
9. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 6, hvor indgivelsen er en gang om ugen.
10. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 6, hvor indgivelsen er en gang hver anden uge.
11. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge krav 6, hvor indgivelsen er en gang om måneden eller en gang hver anden måned.
12. Terapeutisk virksom mængde af en melanocortinreceptor-4-agonist til anvendelse ifølge et af kravene 1-11, hvor den perifere indgivelse af en virksom mængde af en melanocortinreceptor-4-agonist til behandling af insulin-resistensen også reducerer kropsvægten af individet med behov herfor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US193307P | 2007-11-05 | 2007-11-05 | |
PCT/US2008/012490 WO2009061411A2 (en) | 2007-11-05 | 2008-11-05 | Use melanocortins to treat insulin sensitivity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2214693T3 true DK2214693T3 (da) | 2015-11-30 |
Family
ID=40626385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08846334.4T DK2214693T3 (da) | 2007-11-05 | 2008-11-05 | Anvendelse af melanocortiner til behandling af insulinfølsomhed |
Country Status (21)
Country | Link |
---|---|
US (6) | US9155777B2 (da) |
EP (2) | EP2979703B1 (da) |
JP (3) | JP2011502987A (da) |
KR (3) | KR20150013339A (da) |
CN (2) | CN103316345B (da) |
AR (1) | AR069461A1 (da) |
AU (1) | AU2008325194B2 (da) |
BR (1) | BRPI0819188B1 (da) |
CA (2) | CA2704651C (da) |
DK (1) | DK2214693T3 (da) |
ES (2) | ES2690556T3 (da) |
HK (3) | HK1146242A1 (da) |
HU (1) | HUE026842T2 (da) |
IL (2) | IL205554A (da) |
NZ (1) | NZ585131A (da) |
PL (1) | PL2214693T3 (da) |
PT (2) | PT2979703T (da) |
RU (1) | RU2453328C2 (da) |
TR (1) | TR201815292T4 (da) |
TW (1) | TWI374030B (da) |
WO (1) | WO2009061411A2 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2450017C2 (ru) * | 2007-05-25 | 2012-05-10 | Ипсен Фарма С.А.С. | Лиганды меланокортиновых рецепторов, модифицированные гидантоином |
TR201815292T4 (tr) * | 2007-11-05 | 2018-11-21 | Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College | İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi. |
CN102458436B (zh) | 2009-06-08 | 2015-06-03 | 帕拉丁科技公司 | 黑皮质素受体特异性肽 |
WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
CN102548399A (zh) * | 2009-08-05 | 2012-07-04 | 益普生制药股份有限公司 | 黑皮质素治疗血脂异常的用途 |
DK2473518T3 (da) | 2009-08-31 | 2017-03-27 | Tensive Controls Inc | Stabiliserede melanocortin-ligander |
RU2548753C2 (ru) * | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
CA2781402C (en) | 2009-11-23 | 2017-03-21 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
KR20120102716A (ko) | 2009-11-23 | 2012-09-18 | 팔라틴 테크놀로지스 인코포레이티드 | 멜라노코르틴-1 수용체 특이적 선형 펩티드 |
MX341642B (es) * | 2011-06-14 | 2016-08-29 | Ipsen Pharma Sas | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. |
HUE056948T2 (hu) | 2011-12-29 | 2022-04-28 | Rhythm Pharmaceuticals Inc | Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban |
US9534018B2 (en) | 2012-03-13 | 2017-01-03 | Tensive Controls Inc. | Melanocortin analogs having enhanced activity and transport |
CN105518021A (zh) | 2013-03-15 | 2016-04-20 | 节奏制药公司 | 药物组合物 |
EP3450449A3 (en) | 2013-03-15 | 2019-06-12 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
US10314883B2 (en) | 2015-02-13 | 2019-06-11 | University Of Virginia Patent Foundation | Compositions and methods for regulating blood pressure |
WO2017019952A1 (en) | 2015-07-29 | 2017-02-02 | University Of Virginia Patent Foundation | Compositions and methods for regulating leukocyte adhesion |
EP3350200A4 (en) | 2015-09-18 | 2019-03-27 | Wake Forest University Health Services | ANGIOTENSIN ANALOGUES (1-7) AND ASSOCIATED METHODS |
US11124541B2 (en) * | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
US11763106B2 (en) | 2018-06-05 | 2023-09-19 | The Research Foundation For The State University Of New York | Method for passive wireless channel estimation in radio frequency network and apparatus for same |
US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
EP1322954A4 (en) * | 2000-09-13 | 2005-08-03 | Eleanor Roosevelt Inst | METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES |
WO2003099818A1 (en) * | 2002-05-23 | 2003-12-04 | Chiron Corporation | Substituted quinazolinone compounds |
DE60313844T2 (de) * | 2003-03-20 | 2008-01-31 | Santhera Pharmaceuticals (Schweiz) Ag | Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren |
DE602004028228D1 (de) | 2003-03-26 | 2010-09-02 | Merck Sharp & Dohme | Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten |
BRPI0409976A (pt) | 2003-05-09 | 2006-05-09 | Novo Nordisk As | composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto |
CN1784423A (zh) * | 2003-05-09 | 2006-06-07 | 诺沃挪第克公司 | 用于治疗肥胖的肽 |
KR20060026011A (ko) * | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
JP2006527773A (ja) * | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン受容体4(mc4)作用薬とその用途 |
EP1732586A1 (en) | 2004-03-29 | 2006-12-20 | Eli Lilly And Company | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion |
US20080200376A1 (en) * | 2004-10-29 | 2008-08-21 | Maccoss Malcolm | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction |
KR20080041639A (ko) | 2005-07-08 | 2008-05-13 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 멜라노코르틴 수용체의 리간드 |
PL2286825T3 (pl) | 2005-07-08 | 2017-06-30 | Ipsen Pharma | Ligandy receptora melanokortyny |
CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
RU2450017C2 (ru) | 2007-05-25 | 2012-05-10 | Ипсен Фарма С.А.С. | Лиганды меланокортиновых рецепторов, модифицированные гидантоином |
TW200848424A (en) | 2007-06-15 | 2008-12-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
TR201815292T4 (tr) * | 2007-11-05 | 2018-11-21 | Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College | İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi. |
CN102548399A (zh) | 2009-08-05 | 2012-07-04 | 益普生制药股份有限公司 | 黑皮质素治疗血脂异常的用途 |
-
2008
- 2008-11-05 TR TR2018/15292T patent/TR201815292T4/tr unknown
- 2008-11-05 TW TW097142727A patent/TWI374030B/zh active
- 2008-11-05 ES ES15179111.8T patent/ES2690556T3/es active Active
- 2008-11-05 DK DK08846334.4T patent/DK2214693T3/da active
- 2008-11-05 RU RU2010122897/15A patent/RU2453328C2/ru active
- 2008-11-05 CA CA2704651A patent/CA2704651C/en active Active
- 2008-11-05 KR KR1020147036380A patent/KR20150013339A/ko not_active Application Discontinuation
- 2008-11-05 JP JP2010532076A patent/JP2011502987A/ja active Pending
- 2008-11-05 HU HUE08846334A patent/HUE026842T2/en unknown
- 2008-11-05 WO PCT/US2008/012490 patent/WO2009061411A2/en active Application Filing
- 2008-11-05 BR BRPI0819188-3A patent/BRPI0819188B1/pt active IP Right Grant
- 2008-11-05 CN CN201310178847.4A patent/CN103316345B/zh active Active
- 2008-11-05 EP EP15179111.8A patent/EP2979703B1/en active Active
- 2008-11-05 AU AU2008325194A patent/AU2008325194B2/en active Active
- 2008-11-05 ES ES08846334.4T patent/ES2555522T3/es active Active
- 2008-11-05 AR ARP080104846A patent/AR069461A1/es unknown
- 2008-11-05 NZ NZ585131A patent/NZ585131A/xx unknown
- 2008-11-05 US US12/740,917 patent/US9155777B2/en active Active
- 2008-11-05 PL PL08846334T patent/PL2214693T3/pl unknown
- 2008-11-05 EP EP08846334.4A patent/EP2214693B1/en active Active
- 2008-11-05 CA CA2952095A patent/CA2952095C/en active Active
- 2008-11-05 PT PT15179111T patent/PT2979703T/pt unknown
- 2008-11-05 PT PT88463344T patent/PT2214693E/pt unknown
- 2008-11-05 CN CN2008801238931A patent/CN101980717A/zh active Pending
- 2008-11-05 KR KR1020107012327A patent/KR101290623B1/ko active IP Right Grant
- 2008-11-05 KR KR1020137011647A patent/KR101662044B1/ko active IP Right Grant
-
2010
- 2010-05-05 IL IL205554A patent/IL205554A/en active IP Right Grant
-
2011
- 2011-01-19 HK HK11100510.8A patent/HK1146242A1/xx unknown
-
2013
- 2013-02-28 JP JP2013038619A patent/JP5964767B2/ja active Active
- 2013-10-29 HK HK13112170.2A patent/HK1184692A1/zh unknown
-
2015
- 2015-02-26 JP JP2015036512A patent/JP2015131827A/ja active Pending
- 2015-09-03 US US14/844,128 patent/US9439943B2/en active Active
-
2016
- 2016-08-02 HK HK16109223.2A patent/HK1221147A1/zh unknown
- 2016-08-22 US US15/242,866 patent/US9827286B2/en active Active
-
2017
- 2017-01-09 IL IL249998A patent/IL249998B/en active IP Right Grant
- 2017-11-02 US US15/801,432 patent/US20180303899A1/en not_active Abandoned
-
2018
- 2018-12-19 US US16/225,189 patent/US20190111105A1/en not_active Abandoned
-
2022
- 2022-06-03 US US17/831,887 patent/US20220339239A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2214693T3 (da) | Anvendelse af melanocortiner til behandling af insulinfølsomhed | |
Adan et al. | Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat | |
US20130331324A1 (en) | Use of melanocortins to treat dyslipidemia | |
WO2005000877A2 (en) | Novel melanocortin receptor templates, peptides, and use thereof | |
KR20070031440A (ko) | 카켁시아 치료용 시클릭 펩타이드 | |
KR20070032054A (ko) | 카켁시아 치료용 시클릭 펩타이드 |